Inhibition of eEF2 is toxic to mammalian cells due to inhibition of translation, but here, we demonstrate that inhibition of LSG1, and possibly EFL1 by extension, may provide an effective prosenescent cancer therapy with lesser side effects since translation remains unimpaired. The gene discussed is LSG1; the disease is cancer.